Alector's GSK Collaboration Terminated After Drug Failures; Repays $10.4M Loan
ALEC sits 68% above its 52-week low of $1.09.
Summary
Alector announced the termination of its collaboration agreement with GSK following the failure of two key drug candidates, latozinemab and nivisnebart, while also reporting the repayment of a $10.4 million loan.
Key Events · M&A and Partnerships · ALEC
-
GSK Collaboration Terminated
Glaxo Wellcome UK Limited (GSK) provided written notice to terminate the Collaboration and License Agreement, effective January 2, 2027. This follows the failure of latozinemab in Phase 3 and nivisnebart in Phase 2 clinical trials.
-
Loan Repaid and Terminated
Alector repaid in full and terminated a Loan and Security Agreement with Hercules Capital, Inc., totaling $10,428,827.77 in principal, accrued interest, and charges.
Analysis · ALEC · Life Sciences
The termination of the significant collaboration with GSK is a major setback for Alector, directly impacting its pipeline and future revenue potential after both latozinemab and nivisnebart failed clinical trials. While the repayment of a $10.4 million loan improves the balance sheet, it is overshadowed by the loss of a key partnership and the clinical failures that led to it, raising concerns about the company's long-term drug development strategy and financial viability.
At the time of this filing, ALEC was trading at $1.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $203.2M. The 52-week trading range was $1.09 to $3.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.